Biocon Biologics UK is the lead sponsor of 3 current clinical trials in our Brazil, Spain, Turkey and EU (CTIS) registers. 2 are recruiting patients now. All registered phases are Phase 1. The drugs named most often in its trials are Opdivo. The most-studied condition is Melanoma.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
NCT07581509 · ClinicalTrials.gov ↗ · Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)
|
Phase 1 | Recruiting | 2026-06 | Brazil |
|
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
NCT07476326 · ClinicalTrials.gov ↗ · Melanoma
Drug: Opdivo |
Phase 1 | Recruiting | 2026-09 | Spain, Turkey, Brazil |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System with Biocon Biologics UK as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
Pharmacokinetics, safety, and immunogenicity comparison of Bmab1700 and Opdivo® as adjuvant monotherapy in patients with melanoma
2025-525158-20-00 · Neoplasms
|
Phase 1 | Ongoing | Spain, Romania |
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Brazil | 2 | 2 |
| Clinical trials in Spain | 1 | 1 |
| Clinical trials in Turkey | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers.
Sponsors with the most current trials registered for this condition.
Biocon Biologics UK is the lead sponsor of 2 current trials on ClinicalTrials.gov in our Brazil, Spain and Turkey registers, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 4 October 2026. Completed and withdrawn studies are not counted.
Yes. 2 of its 2 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 1 drug or biological as interventions. The most frequent are Opdivo (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 4 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.
